US20200102303A1 - Monoacylglycerol Lipase Modulators - Google Patents

Monoacylglycerol Lipase Modulators Download PDF

Info

Publication number
US20200102303A1
US20200102303A1 US16/586,088 US201916586088A US2020102303A1 US 20200102303 A1 US20200102303 A1 US 20200102303A1 US 201916586088 A US201916586088 A US 201916586088A US 2020102303 A1 US2020102303 A1 US 2020102303A1
Authority
US
United States
Prior art keywords
pyridin
pyrazolo
methanone
dimethyl
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/586,088
Other languages
English (en)
Inventor
Michael K. Ameriks
Gang Chen
Chaofeng Huang
Brian Ngo Laforteza
Suchitra Ravula
Emma Helen Southgate
Wei Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Priority to US16/586,088 priority Critical patent/US20200102303A1/en
Assigned to JANSSEN PHARMACEUTICA NV reassignment JANSSEN PHARMACEUTICA NV ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SOUTHGATE, Emma Helen, HUANG, CHAOFENG, RAVULA, SUCHITRA, AMERIKS, MICHAEL K., CHEN, GANG, LAFORTEZA, Brian Ngo, ZHANG, WEI
Publication of US20200102303A1 publication Critical patent/US20200102303A1/en
Priority to US17/132,313 priority patent/US11820766B2/en
Priority to US18/062,484 priority patent/US20230145249A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention is related to certain fused chemical entities having MGL modulating properties, pharmaceutical compositions comprising these chemical entities, chemical processes for preparing these chemical entities and their use in the treatment of diseases, disorders or conditions associated with MGL receptor activity in subjects, in particular humans.
  • Cannabis Sativa and analogs of ⁇ 9 -tetrahydrocannabinol have been used since the days of folk medicine for therapeutic purposes.
  • the endocannabinoid system consists of two G-protein coupled receptors, cannabinoid receptor type 1 (CB1) (Matsuda et al., Nature, 1990, 346, 561-4) and cannabinoid receptor type 2 (CB2) (Munro et al., Nature, 1993, 365, 61-5).
  • CB1 receptor is one of the most abundant G-protein coupled receptor expressed in the brain (Herkenam et al., Proc. Nat. Acad. Sci., 1990, 87 (5), 1932-1936).
  • CB1 is also expressed peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue and skeletal muscles (Di Marzo et al., Curr Opin Lipidol, 2007, 18, 129-140).
  • CB2 is predominantly expressed in immune cells such as monocytes (Pacher et al., Amer J Physiol, 2008, 294, H1133-H1134) and under certain conditions (inflammation) in the brain ((Benito et al., Brit J Pharmacol, 2008, 153, 277-285) and in skeletal (Cavuoto et al., Biochem Biophys Res Commun, 2007, 364, 105-110) and cardiac muscles (Hajrasouliha et al., Eur J Pharmacol, 2008, 579, 246-252).
  • N-arachidonoylethanolamine (AEA or anandamide) was found to be an endogenous ligand for cannabinoid receptors (Devane et al., Science, 1992, 258, 1946-9). Subsequently, 2-arachidonoylglycerol (2-AG) was also identified as an additional endogenous ligand for the cannabinoid receptors (Mechoulam et al., Biochem Pharmacol, 1995, 50, 83-90; Sugiura et al., Biochem Biophys Res Commun, 1995, 215, 89-97).
  • endocannabinoids signal through a retrograde mechanism. They are synthesized on demand in postsynaptic neurons and then rapidly degraded following binding to presynaptic cannabinoid receptors (Ahn et al., Chem Rev. 2008, 108(5): 1687-707).
  • Monoacylglycerol lipase (MGLL, also known as MAG lipase and MGL) is the serine hydrolase responsible for the degradation of 2-AG into arachidonic acid and glycerol in the central nervous system (Mechoulam et al., Biochem Pharmacol, 1995, 50, 83-90; Sugiura et al., Biochem Biophys Res Commun, 1995, 215, 89-97; Long et al., Nat Chem Biol. 2009 January; 5(1):37-44;), Schlosburg et al, Nat Neurosci., 2010, September; 13(9):1113-9) and peripheral tissues (Long et al., Chem Biol., 2009 Jul. 31; 16(7):744-53).
  • Anandamide is hydrolyzed by fatty acid amide hydrolase (FAAH) (Piomelli, Nat Rev Neurosci, 2003, 4, 873-884).
  • MGL exists in both soluble and membrane bound forms (Dinh et al., Proc Natl Acad Sci USA., 2002, Aug. 6; 99(16):10819-24).
  • MGL is located in presynaptic neurons (Straiker et al., Mol Pharmacol., 2009, December; 76(6):1220-7) and astrocytes (Walter et al., J Neurosci., 2004, Sep. 15; 24(37):8068-74) within regions associated with high CB1 receptor density.
  • genetic ablation of MGL expression produces 10-fold increase in brain 2-AG levels without affecting anandamide concentration (Schlosburg et al., Nat Neurosci., 2010, September; 13(9): 1113-9).
  • MGL modulation offers an interesting strategy for potentiating the cannabinoid system.
  • the primary advantage of this approach is that only brain regions where endocannabinoids are actively produced will be modulated, potentially minimizing the side effects associated with exogenous CB1 agonists.
  • Pharmacological inactivation of MGL by covalent inhibitors in animals increase 2-AG content in brain and peripheral tissues and has been found to produce antinociceptive, anxiolytic and anti-inflammatory effects that are dependent on CB1 and/or CB2 receptors (Long et al., Nat Chem Biol., 2009, Jan. 5(1):37-44; Ghosh et al., Life Sci., 2013, Mar.
  • MGL modulation leads to reduction in proinflammatory prostanoid signaling in animal models of traumatic brain injury (Katz et al., J Neurotrauma., 2015, Mar. 1; 32(5):297-306; Zhang et al., J Cereb Blood Flow Metab., 2015, Mar. 31; 35(4):706), neurodegeneration including Alzheimer's disease (Piro et al., Cell Rep., 2012, Jun. 28, 1(6):617-23; Wenzel et al., Life Sci., 2018, Aug. 15, 207:314-322; Chen et al., Cell Rep., 2012, Nov.
  • Parkinson's disease Nomura et al., Science, 2011, Nov. 11, 334(6057), 809-13; Pasquarelli et al., Neurochem Int., 2017, November, 110:14-24), amyotrophic lateral sclerosis (Pasquarelli et al., Neuropharmacology, 2017, Sep. 15, 124:157-169), multiple sclerosis (Hernadez-Torres et al., Angew Chem Int Ed Engl., 2014, Dec.
  • MGL modulation including MGL inhibition offers a compelling therapeutic approach for the treatment of a vast array of complex diseases.
  • MGL modulation, including MGL inhibition in animals does not produces the full spectrum of neurobehavioral effects observed with ⁇ 9 -tetrahydrocannabinol and other CB1 agonists (Tuo et al., J Med Chem., 2017, Jan. 12, 60(1), 4-46; Mulvihill et al., Life Sci., 2013, Mar. 19, 92(8-9), 492-7).
  • Endocannabinoid hypoactivity is a risk factor for the treatment of depression, anxiety and post-traumatic stress disorders. Millennia of human use of Cannabis sativa , and a brief period in which humans were treated with the endocannabinoid antagonist, rimonabant, provide support for that hypothesis.
  • 2-AG levels are decreased in individuals with major depression (Hill et al., Pharmacopsychiatry., 2008, March; 41(2): 48-53; Hill et al., Psychoneuroendocrinology., 2009, September; 34(8): 1257-1262.). Low circulating 2-AG levels predict rates of depression (Hauer et al., Rev Neurosci., 2012, 23(5-6):681-90).
  • Reduced circulating 2-AG has been found in patient with post-traumatic stress disorder (PTSD) (Hill et al., Psychoneuroendocrinology, 2013, 38 (12), 2952-2961). Healthy volunteers exposed to chronic stressors exhibited progressively diminished circulating 2-AG levels which correlated with the onset of reductions in measures of positive emotions (Yi et al., Progress in Neuro - Psychopharmacology and Biological Psychiatry, 2016, 67 (3), 92-97). The CB1 receptor inverse agonist/antagonist Rimonabant has been withdrawn from the market due to the high incidence of severe depression and suicidal ideation (Christensen et al., The Lancet, 2007, 370, 1706-1713). Therefore, MGL modulators are potentially useful for the treatment of mood disorders, anxiety and PTSD.
  • PTSD post-traumatic stress disorder
  • Cannabinoid receptor agonists are clinically used to treat pain, spasticity, emesis and 5 anorexia (Di Marzo, et al., Annu Rev Med., 2006, 57:553-74; Ligresti et al., Curr Opin Chem Biol., 2009, June; 13(3):321-31). Therefore, MGL modulators, including MGL inhibitors are also potentially useful for these indications.
  • MGL exerts CB1-dependant antinociceptive effects in animal models of noxious chemical, inflammatory, thermal and neuropathic pain (Guindon et al., Br J Pharmacol., 2011, August; 163(7):1464-78; Kinsey et al., J Pharmacol Exp Ther., 2009, September; 330(3):902-10; Long et al., Nat Chem Biol., 2009, January; 5(1):37-44).
  • MGL blockade reduces mechanical and acetone induced cold allodynia in mice subjected to chronic constriction injury of the sciatic nerve (Kinsey et al., J Pharmacol Exp Ther., 2009, September; 330(3):902-10).
  • MGL inhibition produces opiate-sparing events with diminished tolerance, constipation, and cannabimimetic side effects (Wilkerson et al., J Pharmacol Exp Ther., 2016, April; 357(1):145-56).
  • MGL blockade is protective in model of inflammatory bowel disease (Alhouayek et al., FASEB J., 2011, August; 25(8):2711-21).
  • MGL inhibition also reverse Paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced neuropathy (Curry et al., J Pharmacol Exp Ther., 2018, July; 366(1):169-18).
  • MGL inhibitors are also potentially useful for the treatment of chronic inflammatory condition of the urinary bladder like interstitial cystitis (Chinnadurai et al., Med Hypotheses 2019, October; 131: 109321).
  • MGL is upregulated in aggressive human cancer cells and primary tumors where it has a unique role of providing lipolytic sources of free fatty acids for synthesis of oncogenic signaling lipids that promote cancer aggressiveness.
  • MGL in cancer plays a distinct role in modulating the fatty acid precursor pools for synthesis of protumorigenic signaling lipids in malignant human cancer cells.
  • MGL blockade shows anti-emetic and anti-nausea effects in a lithium chloride model of vomiting in shrews (Sticht et al., Br J Pharmacol., 2012, April, 165(8):2425-35).
  • MGL modulators including MGL inhibitors may have utility in modulating drug dependence of opiates.
  • MGL blockade reduce the intensity of naloxone-precipitated morphine withdrawal symptoms in mice.
  • MGL blockade also attenuated spontaneous withdrawal signs in morphine-dependent mice (Ramesh et al., J Pharmacol Exp Ther., 2011, October, 339(1):173-85).
  • MGL modulators are also potentially useful for the treatment of eye conditions, including but not limited to, glaucoma and disease states arising from elevated intraocular pressure (Miller et al., Pharmaceuticals, 2018, 11, 50).
  • Embodiments of the present invention relate to chemical entities, pharmaceutical compositions containing them, methods of making and purifying them, and methods for using them the treatment of diseases, disorders, and conditions associated with the MGL modulation.
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with the MGL modulation using at least one chemical entity of the invention.
  • Embodiments of this invention are compounds of Formula (I),
  • R 2 is selected from the group consisting of:
  • R 3 is selected from the group consisting of:
  • R 4 is selected from the group consisting of: C 1-4 alkyl
  • R 3 is cyclopropyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
  • Embodiments of this invention are also compounds of Formula (II),
  • R 1 is C 1-4 alkyl
  • R 2a is selected from the group consisting of:
  • R 3a is selected from the group consisting of:
  • alkyl refers to a straight- or branched-chain alkyl group having from 1 to 8 carbon atoms in the chain.
  • alkyl groups include methyl (Me), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
  • C 1 -C 4 alkyl refers to straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain.
  • cycloalkyl refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle.
  • Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:
  • halogen or “halo” represents chlorine, fluorine, bromine, or iodine.
  • haloalkyl refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens.
  • C 1 -C 4 haloalkyl refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain, optionally substituting hydrogens with halogens.
  • haloalkyl groups include trifluoromethyl (CF 3 ), difluoromethyl (CF 2 H), monofluoromethyl (CH 2 F), pentafluoroethyl (CF 2 CF 3 ), tetrafluoroethyl (CHFCF 3 ), monofluoroethyl (CH 2 CH 2 F), trifluoroethyl (CH 2 CF 3 ), tetrafluorotrifluoromethylethyl (CF(CF 3 ) 2 ), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.
  • aryl refers to a monocyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having 6 atoms per ring (Carbon atoms in the aryl groups are sp2 hybridized.)
  • phenyl represents the following moiety:
  • heteroaryl refers to an aromatic monocyclic or multicyclic ring system comprising 5 to 14 ring atoms, wherein from 1 to 4 of the ring atoms is independently O, N or S and the remaining ring atoms are carbon atoms.
  • a heteroaryl group has 5 to 10 ring atoms.
  • a heteroaryl group is monocyclic and has 5 or 6 ring atoms.
  • a heteroaryl group is monocyclic and has 5 or 6 ring atoms and at least one nitrogen ring atom.
  • heteroaryl group is joined via a ring carbon atom and any nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide.
  • heteroaryl also encompasses a heteroaryl group, as defined above, which has been fused to a benzene ring.
  • 5-membered heteroaryl refers to a heteroaryl group, as defined above, which has 5 ring atoms.
  • Non-limiting examples of illustrative 5-membered heteroaryls include:
  • 6-membered heteroaryl refers to a heteroaryl group, as defined above, which has 6 ring atoms.
  • Non-limiting examples of illustrative 6-membered heteroaryls include:
  • 5,6-fused bicyclic heteroaryl or 6,5-fused bicyclic heteroaryl refers to a heteroaryl group, as defined above, which has 9 ring atoms.
  • Non-limiting examples of illustrative 5,6-fused bicyclic heteroaryl or 6,5-fused bicyclic heteroaryl include:
  • 6,6-fused bicyclic heteroaryl refers to a heteroaryl group, as defined above, which has 9 ring atoms.
  • Non-limiting examples of illustrative 6,6-fused bicyclic heteroaryl include:
  • heterocycloalkyl refers to a ring system which is non-aromatic, 1 to 4 of the ring atoms is independently O, N or S and the remaining ring atoms are carbon atoms, which may optionally be fused to another ring (aromatic or heteroaromatic).
  • Non-limiting examples of illustrative 6,6-fused bicyclic heteroaryl include:
  • substituted means that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
  • variable point of attachment means that a group is allowed to be attached at more than one alternative position in a structure.
  • the attachment will always replace a hydrogen atom on one of the ring atoms.
  • all permutations of bonding are represented by the single diagram, as shown in the illustrations below.
  • substituted means that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • optionally substituted means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.
  • any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms.
  • compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of such formula.
  • the compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (R)- or (S)-stereoisomers or as mixtures thereof.
  • any formula given herein is intended to represent a racemate, one or more of its enantiomeric forms, one or more of its diastereomeric forms, and mixtures thereof.
  • any formula given herein is intended to refer also to any one of hydrates, solvates, polymorphs and of such compounds, and mixtures thereof, even if such forms are not listed explicitly.
  • R at a stereocenter designates that the stereocenter is purely of the R-configuration as defined in the art; likewise, the term “S” means that the stereocenter is purely of the S-configuration.
  • RS refers to a stereocenter that exists as a mixture of the R- and S-configurations.
  • Compounds containing one stereocenter drawn without a stereo bond designation are a mixture of 2 enantiomers.
  • Compounds containing 2 stereocenters both drawn without stereo bond designations are a mixture of 4 diastereomers.
  • Compounds with 2 stereocenters both labeled “RS” and drawn with stereo bond designations are a 2-component mixture with relative stereochemistry as drawn.
  • Unlabeled stereocenters drawn without stereo bond designations are a mixture of the R- and S-configurations. For unlabeled stereocenters drawn with stereo bond designations, the absolute stereochemistry is as depicted.
  • references to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named.
  • reference herein to a compound such as R—COOH encompasses reference to any one of, for example, R—COOH(s), R—COOH(sol), and R—COO-(sol).
  • R—COOH(s) refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation
  • R—COOH(sol) refers to the undissociated form of the compound in a solvent
  • R—COO-(sol) refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from R—COOH, from a salt thereof, or from any other entity that yields R—COO— upon dissociation in the medium being considered.
  • an expression such as “exposing an entity to compound of formula R—COOH” refers to the exposure of such entity to the form, or forms, of the compound R—COOH that exists, or exist, in the medium in which such exposure takes place.
  • an expression such as “reacting an entity with a compound of formula R—COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R—COOH that exists, or exist, in the medium in which such reacting takes place.
  • any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
  • Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number in an enriched form.
  • isotopes that can be incorporated into compounds of the invention in a form that exceeds natural abundances include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as 2 H (or chemical symbol D), 3 H (or chemical symbol T), 11 C, 13 C, 14 C, 15 N, 18 O, 17 O, 31 P, 32 P, 35 S, 18 F, 36 Cl, and 125 I, respectively.
  • Such isotopically labelled compounds are useful in metabolic studies (preferably with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques [such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F or 11 C labeled compound may be particularly preferred for PET or SPECT studies.
  • substitution with heavier isotopes such as deuterium (i.e., 2 H, or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements.
  • Isotopically labeled compounds of this invention can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • C n-m alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies n ⁇ N ⁇ m, with m>n.
  • each of groups Q and R can be H or F
  • the choice of H or F for Q is made independently of the choice of H or F for R, so the choice of assignment for Q does not determine or condition the choice of assignment for R, or vice-versa, unless it is expressly indicated otherwise.
  • Illustrative claim recitation in this regard would read as “each of Q and R is independently H or F”, or “each of Q and R is independently selected from the group consisting of H and F”.
  • a zwitterionic compound would be encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its zwitterionic form.
  • Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names.
  • the name zwitterion is assigned the name identification CHEBI:27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities.
  • a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign.
  • aminoethanoic acid (the amino acid glycine) has the formula H 2 NCH 2 COOH, and it exists in some media (in this case in neutral media) in the form of the zwitterion + H 3 NCH 2 COO ⁇ .
  • Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well-established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art.
  • embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof.
  • substituent S example is one of S 1 , S 2 , and S 3
  • this listing refers to embodiments of this invention for which S example is S 1 ; S example is S 2 ; S example is S 3 ; S example is one of Si and S 2 ; S example is one of Si and S 3 ; S example is one of S 2 and S 3 ; S example is one of S 1 , S 2 and S 3 ; and S example is any equivalent of each one of these choices.
  • C i -C j when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j, is independently realized.
  • the term C 1 -C 3 refers independently to embodiments that have one carbon member (C 1 ), embodiments that have two carbon members (C 2 ), and embodiments that have three carbon members (C 3 ).
  • a “pharmaceutically acceptable salt” is intended to mean a salt of an acid or base of a compound represented by Formula (I) (as well as compounds of Formula (II)) that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, S. M. Berge, et al., “Pharmaceutical Salts”, J. Pharm. Sci., 1977, 66:1-19, and Handbook of Pharmaceutical Salts, Properties, Selection, and Use , Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002.
  • Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.
  • a compound of Formula (I) (as well as compounds of Formula (II)) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.
  • Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phen
  • Compounds of Formula (I) may contain at least one nitrogen of basic character, so desired pharmaceutically acceptable salts may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an alpha-hydroxy acid,
  • an inorganic acid such as hydrochlor
  • Compounds of Formula (I) may contain a carboxylic acid moiety, a desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
  • an inorganic or organic base such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology.
  • suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and tertiary amines, and cyclic amines, such as benzylamines, pyrrolidines, piperidine, morpholine, piperazine, N-methyl-glucamine and tromethamine and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • amino acids such as glycine and arginine
  • ammonia carbonates, bicarbonates, primary, secondary, and tertiary amines
  • cyclic amines such as benzylamines, pyrrolidines, piperidine, morpholine, piperazine, N-methyl-glucamine and tromethamine
  • inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.
  • active agent or “active agents” of the present invention are useful as MGL-modulators in the methods of the invention.
  • Such methods for modulating MGL comprise the use of a therapeutically effective amount of at least one chemical entity of the invention.
  • the MGL modulator is an inhibitor and is used in a subject diagnosed with or suffering from a disease, disorder, or condition associated with MGL receptor activity, such as those described herein. Symptoms or disease states are intended to be included within the scope of “disease, disorders or conditions.”
  • the invention relates to methods of using the active agents described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition associated with the MGL receptor activity.
  • treat or “treating” as used herein is intended to refer to administration of an active agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of MGL receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition associated with the MGL modulation.
  • subject refers to a mammalian patient in need of such treatment, such as a human.
  • composition refers to a product that includes the specified ingredients in therapeutically effective amounts, as well as any product that results, directly, or indirectly, from combinations of the specified ingredients in the specified amounts.
  • MGL inhibitor is intended to encompass a compound that interacts with MGL to substantially reduce or eliminate its catalytic activity, thereby increasing the concentrations of its substrate(s).
  • MGL-modulated is used to refer to the condition of being affected by the modulation of the MGL enzyme including the condition of being affected by the inhibition of the MGL enzyme.
  • the disclosure is directed to methods for treating, ameliorating and/or preventing diseases, conditions, or disorders associated with pain (including inflammatory pain), and also psychiatric disorders, neurological disorders, cancers and eye conditions by the administration of therapeutically effective amounts of MGL modulators to subjects in need thereof.
  • modulators include both inhibitors and activators, where “inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize, or down-regulate the MGL expression or activity, and “activators” are compounds that increase, activate, facilitate, sensitize, or up-regulate MGL expression or activity.
  • the term “affect” or “affected” when referring to a disease, condition or disorder that is affected by inhibition of MGL) includes a reduction in the frequency and/or severity of one or more symptoms or manifestations of said disease, condition or disorder; and/or include the prevention of the development of one or more symptoms or manifestations of said disease, condition or disorder or the development of the disease, condition or disorder.
  • a therapeutically effective amount of at least one active agent according to the invention is administered to a subject suffering from or diagnosed as having such a disease, disorder, or condition.
  • a “therapeutically effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in subjects in need of such treatment for the designated disease, disorder, or condition.
  • Effective amounts or doses of the active agents of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
  • routine factors e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
  • routine factors e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician.
  • the dose may be adjusted for preventive or maintenance treatment.
  • the dosage or the frequency of administration, or both may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained.
  • treatment may cease.
  • Subjects may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms.
  • the compounds of the invention are envisaged for use alone, in combination with one or more of other compounds of this invention, or in combination with additional active ingredients in the treatment of the conditions discussed below.
  • the additional active ingredients may be co-administered separately with at least one compound of the invention, with active agents of the invention or included with such an agent in a pharmaceutical composition according to the invention.
  • additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases associated with the MGL modulation, such as another MGL inhibitor or a compound active against another target associated with the particular condition, disorder, or disease.
  • the combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.
  • an “effective amount” means an amount sufficient to affect MGL modulation.
  • a pharmaceutical composition of the invention comprises a therapeutically effective amount of at least one active agent in accordance with the invention.
  • compositions commonly used in pharmaceutical compositions are substances that are non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith.
  • excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.
  • compositions containing one or more dosage units of the active agents may be prepared using pharmaceutically acceptable excipients and compounding techniques known or that become available to those of ordinary skill in the art.
  • the compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
  • the preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories.
  • the compositions may be formulated for any one of a plurality of administration routes, such as intravenous infusion, topical administration, or oral administration.
  • the compositions may be formulated for oral administration.
  • the active agents of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension.
  • the active agents may be formulated to yield a dosage of, e.g., for a 70-kg human, an illustrative range for a suitable dosage amount is from about 1 to 1000 mg/day in single or multiple dosage units.
  • Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
  • suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
  • Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
  • Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary disintegrating agents.
  • Binding agents may include starch and gelatin.
  • the lubricating agent if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
  • Capsules for oral administration include hard and soft gelatin or (hydroxypropyl)methyl cellulose capsules.
  • active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent.
  • Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water; preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
  • suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like
  • non-aqueous vehicles e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water
  • compositions may be formulated for rectal administration as a suppository, enema or foam.
  • parenteral use including intravenous, intramuscular, intraperitoneal, or subcutaneous routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Such forms may be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation.
  • Illustrative infusion doses range from about 1 to 1000 ⁇ g/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
  • the agents may be mixed with a pharmaceutical carrier at a concentration of about 0.01% to about 20% of drug to vehicle, preferably 0.1% to 10%.
  • a pharmaceutical carrier for topical administration, may be mixed with a pharmaceutical carrier at a concentration of about 0.01% to about 20% of drug to vehicle, preferably 0.1% to 10%.
  • Another mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.
  • Active agents may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.
  • the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with MGL modulation, comprising administering to the subject in need of such treatment a therapeutically effective amount of the active agent.
  • the compounds of Formula (I) and Formula (II) are useful in methods for treating, ameliorating and/or preventing a disease, a condition or a disorder that is affected by the inhibition of MGL.
  • Such methods comprise administering to a subject, including an animal, a mammal, and a human in need of such treatment, amelioration and/or prevention, a therapeutically effective amount of a compound of Formula (I), Formula (II), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.
  • the compounds of Formula (I), Formula (II), or pharmaceutically acceptable salts, isotopes, N-oxides, solvates and stereoisomers thereof are useful for treating, ameliorating and/or preventing diseases, conditions, or disorders causing pain, psychiatric disorders, neurological disorders, cancers and eyes conditions.
  • the compounds of Formula (I), Formula (II), or pharmaceutically acceptable salts, isotopes, N-oxides, solvates and stereoisomers thereof are useful for treating, ameliorating and/or preventing inflammatory pain, major depressive disorder, treatment resistant depression, anxious depression or bipolar disorder by administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I), Formula (II), or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof as herein defined.
  • inflammatory pain examples include, but are not limited to, pain due to a disease, condition, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post-operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity, itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis, pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.
  • inflammatory hyperalgesia is inflammatory hyperalgesia/hypersensitivity.
  • inflammatory hyperalgesia include a disease, condition, disorder, or pain state including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post-operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity and/or dermal allergy, itch, eczema, pharyngitis, enteritis, irritable bowel syndrome, inflammatory bowel diseases including Crohn's Disease, ulcerative colitis, benign prostatic hypertrophy, and nasal hypersensitivity.
  • the present invention is directed to a method for treating, ameliorating and/or preventing inflammatory visceral hyperalgesia in which an enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) (as well as compounds of Formula (II)) or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof.
  • the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) (as well as compounds of Formula (II)), or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof.
  • a further embodiment of the present invention is directed to a method for treating, ameliorating and/or preventing neuropathic pain.
  • a neuropathic pain include pain due to a disease, condition, disorder, or pain state including cancer, neurological disorders, spine and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis, polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II (CRPS I/II), radiculopathy, Guillain-Barre syndrome, meralgia paresthetica,
  • neuropathic cold allodynia which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling stimuli exists.
  • neuropathic cold allodynia include allodynia due to a disease, condition, disorder or pain state including neuropathic pain (neuralgia), pain arising from spine and peripheral nerve surgery or trauma, traumatic brain injury (TBI), trigeminal neuralgia, postherpetic neuralgia, causalgia, peripheral neuropathy, diabetic neuropathy, central pain, stroke, peripheral neuritis, polyneuritis, complex regional pain syndrome I and II (CRPS I/II) and radiculopathy.
  • neuropathic pain neuralgia
  • TBI traumatic brain injury
  • trigeminal neuralgia postherpetic neuralgia
  • causalgia peripheral neuropathy
  • diabetic neuropathy central pain
  • stroke peripheral neuritis
  • polyneuritis complex regional pain syndrome I and II (CRPS I/II
  • the present invention is directed to a method for treating, ameliorating and/or preventing neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) (as well as compounds of Formula (II)) or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof.
  • Examples of psychiatric disorders include, but are not limited to, anxieties such as, social anxiety, post-traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive-compulsive disorder, acute stress disorder, separation anxiety disorder, and generalized anxiety disorder, as well as depression such as, major depression, bipolar disorder, seasonal affective disorder, post-natal depression, manic depression, and bipolar depression, mood disorders and mood affective disorders that can be treated according to the present invention include, but are not limited to, bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, anxious depression, bipolar disorder, depressive disorder with postpartum onset, depressive disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder; psychoses.
  • anxieties such
  • neurological disorder examples include, but are not limited to, tremors, dyskinesias, dystonias, spasticity, Tourette's Syndrome; neuromyelitis optica, Parkinson's disease; Alzheimer's disease; senile dementia; Huntington's disease; Epilepsy/seizure disorders and sleep disorders.
  • cancers include, but are not limited to, benign skin tumors, prostate tumors, ovarian tumors and cerebral tumors (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumors of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, neuroepitheliomas, epiphyseal tumor, ependymoblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, schwannomas).
  • eye conditions include, but are not limited to, ocular hypertension, glaucoma, degeneration and apoptosis of retinal ganglion cells and neuroretinal cells.
  • inventions of this invention provide for a method for modulating MGL receptor activity, including when such receptor is in a subject, comprising exposing MGL receptor to a therapeutically effective amount of at least one compound selected from compounds of the invention.
  • Embodiments of this invention are compounds of Formula (I),
  • R 2 is selected from the group consisting of:
  • R 3 is selected from the group consisting of:
  • R 4 is selected from the group consisting of: C 1-4 alkyl
  • R 3 is cyclopropyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 2 is
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 3 is phenyl, 3,5-difluorophenyl, 3-chlorophenyl, 3-fluorophenyl, or 3-(difluoromethoxy)phenyl.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 3 is cyclopropyl.
  • An additional embodiment of the invention is a compound of Formula (I) wherein R 4 is CH 3 .
  • An additional embodiment of the invention is a compound of Formula (I) wherein X is O.
  • An additional embodiment of the invention is a compound of Formula (I) wherein X is S.
  • An additional embodiment of the invention is a compound of Formula (I) wherein X is NH or NCH 3 .
  • a further embodiment of the current invention is a compound as shown below in Table 1.
  • R 2 is selected from the group consisting of:
  • R 3 is selected from the group consisting of:
  • R 4 is selected from the group consisting of: C 1-4 alkyl
  • R 3 is cyclopropyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of compounds of Formula (I);
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound in Table 1, as well as and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of compounds of Table 1, pharmaceutically acceptable prodrugs of compounds of Table 1, and pharmaceutically active metabolites of Table 1; and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (I):
  • R 2 is selected from the group consisting of:
  • R 3 is selected from the group consisting of:
  • R 4 is selected from the group consisting of: C 1-4 alkyl
  • R 3 is cyclopropyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, to a subject in need thereof.
  • An additional embodiment of the invention is a compound of Formula (II) wherein
  • R 1 is C 1-4 alkyl
  • R 2a is selected from the group consisting of:
  • R 3a is selected from the group consisting of:
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • R f is H, F, CH 3 , CF 3 , or OCH 3 .
  • An additional embodiment of the invention is a compound of Formula (II) wherein R e is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 2a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 3a is phenyl; or phenyl substituted with one member selected from the group consisting of: F, Cl, OCH 3 , OCH 2 CH 3 , OCH(CH 3 ) 2 , OCHF 2 , CF 3 , CF 2 CH 3 , OCF 2 H, and OCF 3 .
  • R 3a is phenyl substituted with two or three members independently selected from the group consisting of: F, Cl, CH 3 , CF 2 H, OCF 2 H and OCH 3 .
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 3a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 3a is
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 4a is CH 3 .
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 4a is CF 3 .
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 4a is CF 2 H.
  • An additional embodiment of the invention is a compound of Formula (II) wherein R 4a is phenyl.
  • An additional embodiment of the invention is a compound of Formula (II) having the Formula
  • R 1 is CH 3 ;
  • R 2a is selected from the group consisting of:
  • R 4a is CH 3 or phenyl
  • each R n is independently selected from the group consisting of: H, Cl and F;
  • n 1, 2, or 3.
  • R 1 is CH 3 ;
  • R f is selected from the group consisting of H, F and OCH 3 ;
  • R j is selected from the group consisting of: H, Cl, F and CF 3 ;
  • R k is selected from the group consisting of: H, Br, CH 3 , CF 3 , OH, and OCH 2 CH 2 F;
  • R m is H or CH 3 ;
  • R p is selected from the group consisting of: H, CH 3 , and OCH 3 ;
  • R 3a is 3-chlorophenyl or 3,4,5-trifluorophenyl.
  • a further embodiment of the current invention is a compound as shown below in Table 2.
  • An additional embodiment of the invention is a compound selected from the group consisting of compounds of Formula (I), Formula (II), Formula (IIA), Formula (IIB), or Formula (IIC), or Formula (IID), or Formula (IIE), or Formula (IIF), or a combination thereof.
  • An additional embodiment of the invention is a pharmaceutical composition comprising:
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IIA), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIA), pharmaceutically acceptable prodrugs of compounds of Formula (IIA), and pharmaceutically active metabolites of Formula (IIA); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IIB), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIB), pharmaceutically acceptable prodrugs of compounds of Formula (IIB), and pharmaceutically active metabolites of Formula (IIB); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IIC), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIC), pharmaceutically acceptable prodrugs of compounds of Formula (IIC), and pharmaceutically active metabolites of Formula (IIC); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IID), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IID), pharmaceutically acceptable prodrugs of compounds of Formula (IID), and pharmaceutically active metabolites of Formula (IID); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IIE), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIE), pharmaceutically acceptable prodrugs of compounds of Formula (IIE), and pharmaceutically active metabolites of Formula (IIE); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IIF), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IIF), pharmaceutically acceptable prodrugs of compounds of Formula (IIF), and pharmaceutically active metabolites of Formula (IIF); and at least one pharmaceutically acceptable excipient.
  • An additional embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a therapeutically effective amount of at least one compound in Table 2, as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Table 2, pharmaceutically acceptable prodrugs of compounds of Table 2, and pharmaceutically active metabolites of Table 2; and at least one pharmaceutically acceptable excipient.
  • compositions of Formula (I) are also within the scope of the invention.
  • pharmaceutically acceptable prodrugs of compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)
  • pharmaceutically active metabolites of the compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)
  • pharmaceutically acceptable prodrugs of compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)
  • pharmaceutically active metabolites of the compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)
  • isotopic variations of compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)), such as, e.g., deuterated compounds of Formula (I), or Formula (II).
  • pharmaceutically acceptable salts, N-oxides or solvates of the isotopic variations of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)).
  • compositions of Formula (I) are also within the scope of the invention.
  • pharmaceutically acceptable prodrugs of the isotopic variations of the compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)
  • pharmaceutically active metabolites of the isotopic variations of the compounds of Formula (I) as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)).
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (II):
  • R 3a is selected from the group consisting of:
  • R 4a is selected from the group consisting of: CH 3 , CF 2 H, CF 3 , C 3-6 cycloalkyl, and phenyl; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, to a subject in need thereof.
  • An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)), enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)), isotopic variations of the compounds of Formula (I) (as well as Formulas (II), (IIA), (IIB), (IIC), (IID), (IIE) and (IIF)), and pharmaceutically acceptable salts of all of the foregoing.
  • compounds of Formula (I) as well as Formulas (II), (IIA), (I
  • a compound of formula (III) is prepared by condensation of commercially available or synthetically accessible 2-amino-4-aminobenzoic acid; with 1,2-dioxoalkanes such as 2-oxopropanal, 2,3-butanedione, and the like; in a suitable solvent such as EtOH and the like; at a temperature of 80° C.; for a period of about 1-16 hours; to provide a compound of formula (III), where R f is H or CH 3 .
  • methyl 2-hydroxyquinoxaline-6-carboxylate is prepared by condensation of commercially available or synthetically accessible 2-amino-4-aminobenzoic acid; with ethyl 2-oxoacetate; in a suitable solvent such as ethanol (EtOH) and the like; at room temperature; for a period of 1 hour.
  • Halogenation of methyl 2-hydroxyquinoxaline-6-carboxylate is achieved with a chlorinating reagent, such as thionyl chloride; neat, or in a suitable solvent such as toluene, and the like; followed by catalytic amount of N,N-dimethylformamide (DMF); at reflux temperature; to provide methyl 2-chloroquinoxaline-6-carboxylate.
  • a compound of formula (IV) is prepared in two steps.
  • a first step palladium catalyzed reductive deuteration of methyl 2-chloroquinoxaline-6-carboxylate; using a commercially available deuterated reagent such as sodium borodeuteride; in presence of a palladium catalyst such as [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl 2 (dppf)), and the like; a base such as tetramethylethylenediamine (TMEDA or TEMED); in a suitable solvent such as tetrahydrofuran (THF), and the like; at room temperature; for a period of 1 hour.
  • TMEDA or TEMED tetramethylethylenediamine
  • THF tetrahydrofuran
  • a second step saponification of the ester to the acid is achieved employing conditions known to one skilled in the art. For example, employing a suitable base such as NaOH, LiOH, and the like; in a suitable solvent such as water, THF, methanol (MeOH), or a mixture thereof; at room temperature; for a period of about 1 h; provides a compound of formula (IV), where M is lithium.
  • a suitable base such as NaOH, LiOH, and the like
  • a suitable solvent such as water, THF, methanol (MeOH), or a mixture thereof
  • methyl quinoline-6-carboxylate is halogenated under conditions known to one skilled in the art.
  • reaction of methyl quinoline-6-carboxylate; with a halogenating agent such as N-bromosuccinimide (NBS), N-iodosuccinimide (NIS), and the like in a suitable solvent such as acetic acid (AcOH); at a temperature of about 100° C.; for a period of 2-4 h; provides a compound of formula (V).
  • the halogenating agent is NIS, for a compound of formula (V), where Hal is I.
  • the iodo-substituent allows the insertion of the trifluoromethyl moiety via (trifluoromethyl)copper-mediated trifluoromethylation, employing a trifluormethylating agent such as trifluoromethyl iodide, sodium trifluoroacetate, methyl 2,2-difluoro-2-(fluorosulfonyl)acetate, trifluoromethyl-trimethylsilane, trifluoromethyl-triethylsilane, methyl chlorodifluoroacetate-potassium fluoride, and the like, (methyl2,2-difluoro-2-(fluorosulfonyl)acetate is preferred); a catalyst such as copper iodide, copper bromide, or other such copper salts, and copper powder (copper iodide is preferred), in an inert solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide, N
  • Saponification of the ester to the acid is achieved employing conditions known to one skilled in the art, for example, using a suitable base such as NaOH, LiOH, and the like, in a suitable solvent such as water/THF/MeOH, at a temperature of about 60° C., for a period of about 2 h, to provide 3-(trifluoromethyl)quinoline-6-carboxylic acid.
  • a suitable base such as NaOH, LiOH, and the like
  • a suitable solvent such as water/THF/MeOH
  • a compound of formula (VI), where R a is H or halo, is alkylated with a suitable alkyl halide such as 1-iodoethane, fluoro-2-iodoethane, and the like; a suitable base such as Cs 2 CO 3 , K 2 CO 3 , and the like; in a suitable solvent such as N,N-dimethylformamide.
  • a suitable alkyl halide such as 1-iodoethane, fluoro-2-iodoethane, and the like
  • a suitable base such as Cs 2 CO 3 , K 2 CO 3 , and the like
  • a suitable solvent such as N,N-dimethylformamide
  • compounds of formulas (IXa), (IXb) and (IXc) are prepared under conditions known to one skilled in the art, by condensation of commercially available or synthetically accessible substituted pyridine, pyridazine and pyrazine amines of formulas (VIIIa), (VIIIb) and (VIIIc) where R i is independently H, C 1-4 alkyl, C 1-4 haloalkyl, OC 1-4 alkyl, and C 3-6 cycloalkyl; using ethyl 2-chloro-3-oxobutanoate in suitable solvents such as 1,2-dimethoxy ethane (DME), and the like; at temperature of 90° C., for a period of about 2-16 hours.
  • DME 1,2-dimethoxy ethane
  • Saponification of the esters (IXa), (IXb) and (IXc) to the corresponding acid is achieved employing conditions known to one skilled in the art, for example, using a suitable base such as potassium trimethylsilanolate (TMSOK), NaOH, LiOH, and the like, in a suitable solvent such as water/THF/MeOH, at a temperature of about 60° C., for a period of about 24 h, to provide compounds of formulas (Xa), (Xb), and (Xc), where M is potassium, Na, or Li, preferably potassium.
  • a suitable base such as potassium trimethylsilanolate (TMSOK), NaOH, LiOH, and the like
  • TMSOK potassium trimethylsilanolate
  • NaOH NaOH
  • LiOH LiOH
  • a suitable solvent such as water/THF/MeOH
  • Saponification employing basic conditions, using a suitable base such as TMSOK, NaOH, LiOH, and the like; in a suitable solvent such as water, THF, MeOH, or a mixture thereof; at a temperature of about 60° C.; for a period of about 24 h; provides a compound of formula (XIIIb) where M is potassium, Na, or Li; preferably potassium.
  • a suitable base such as TMSOK, NaOH, LiOH, and the like
  • a suitable solvent such as water, THF, MeOH, or a mixture thereof
  • a compound of formula (XIVa), where R i is C 3-6 cycloalkyl substituted with C 1-4 alkyl, is treated with dimethylcarbonate; and a suitable base such as potassium tert-butoxide, and the like; in a suitable solvent such as toluene, and the like; at a temperature of about 75° C.; to provide a compound of (XV), where R m is methyl.
  • a compound of formula (XIVb), where R i is an optionally substituted C 3-6 cycloalkyl is reacted with oxalyl chloride; ethyl potassium malonate; in the presence of magnesium chloride; a suitable base such as triethylamine, and the like; in a suitable solvent such as ethyl acetate, THF, or a mixture thereof; to provide a compound of formula (XV), where R m is ethyl.
  • a suitable base such as NaOH, LiOH, KOH, and the like, preferably LiOH
  • a suitable solvent such as water, THF, MeOH, or a mixture thereof; at a temperature of about 60° C.; for a period of about 24 h; to provide compounds of formulas (XXa), (XXb), and (XXc), where M is potassium, Na, or Li, preferably potassium.
  • a suitable alkylating agent such as methyl iodide (MeI)
  • a suitable base such as NaH, and the like
  • a suitable solvent such as THF, and the like
  • hydrolysis of methyl 5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylate is achieved employing conditions previously described, to provide potassium 5,7-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-4-carboxylate.
  • an alkyl stannane such as tributyl(1-ethoxyvinyl)stannane
  • a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride (Pd(PPh 3
  • Oxidation of 4-(1-ethoxyvinyl)-1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidine employing oxidation conditions such as sodium periodate; potassium permanganate; in suitable solvent such as 1,4 dioxane, and the like; at a temperature of about room temperature; for a period of 18 h; and neutralized with aqueous potassium carbonate solution; provides a mixture of ethyl 1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidine-4-carboxylate and 1,6-dimethyl-1H-pyrazolo[3,4-d]pyrimidine-4-carboxylic acid (WO 2015/025026; Page-96).
  • oxidation conditions such as sodium periodate; potassium permanganate; in suitable solvent such as 1,4 dioxane, and the like
  • 6,6-dimethylmorpholine-3-carboxylic acid is prepared in two steps from 4-(tert-butyl) 3-methyl 6,6-dimethylmorpholine-3,4-dicarboxylate.
  • deprotection of BOC group is achieved according to procedures known to one skilled in the art and employing established methodologies, such as those described in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis,” 3 ed., John Wiley & Sons, 1999, pgs 518-525.
  • deprotection under acidic conditions such as trifluoroacetic acid (TFA)/CH 2 Cl 2 , HCl/Dioxane, and the like, at room temperature for a period of 2 h.
  • acidic conditions such as trifluoroacetic acid (TFA)/CH 2 Cl 2 , HCl/Dioxane, and the like
  • suitable base such as NaOH and the like
  • MeOH/water a solvent
  • Diazotization of 6,6-dimethylmorpholine-3-carboxylic acid is achieved employing sodium nitrite; in water; under acidic conditions such as conc. HCl; at temperatures ranging from 0° C. to room temperature; for a period of 16 h.
  • TFAA trifluoroacetic anhydride
  • ACN acetonitrile
  • a suitable base such as NaOH, LiOH, KOH, and the like
  • a suitable solvent such as water, THF, MeOH, or a mixture thereof; at a temperature of about 60° C.; for a period of about 24 h; to provide compounds of formulas (XXIa) and (XXIb), where M is K, Na, or Li.
  • a keto-ester compound of formula (XXV), where PG is a suitable protecting group such as BOC (tert-butyloxycarbonyl), and R 1 is C 1-4 alkyl is prepared from a commercially available or synthetically accessible compound of formula (XXIV).
  • a compound of formula (XXIV), where PG is BOC is converted to compound (XXV), by treatment with a strong base such as LHMDS, in a suitable solvent such as THF, and the like, at a temperature of about ⁇ 78° C.; for 30 minutes, followed by treatment with ethyl cyanoformate at ⁇ 78° C., for a period of about 2 hours.
  • a compound of formula (XXIII) is prepared in two steps from a compound of formula (XXII), where R 1 is C 1-4 alkyl.
  • a compound of formula (XXII) is alkylated with ethyl 4-bromobutanoate; employing potassium iodide; a suitable base such as dibasic potassium phosphate.
  • BOC protection employing established methodologies, such as those described in T. W. Greene and P. G. M. Wuts, “Protective Groups in Organic Synthesis,” 3 ed., John Wiley & Sons, 1999, pgs 518-525, provides a compound of formula (XXIII).
  • ethyl L-alaninate hydrochloride is alkylated by treatment with bromobutanoate and potassium iodide in the presence of a suitable base such as dibasic potassium phosphate in a suitable solvent such as DMF.
  • a suitable base such as dibasic potassium phosphate
  • a suitable solvent such as DMF.
  • the amine moiety is protected with a carbamate protecting group such as tert-butyloxycarbonyl (BOC). Cyclization of the diester occurs under Dieckmann condensation conditions known to one skilled in the art.
  • ethyl (S)-4-((tert-butoxycarbonyl)(1-ethoxy-1-oxopropan-2-yl)amino)butanoate is treated with lithium bis(trimethylsilyl)amide (LiHMDS) at a suitable temperature range such as between ⁇ 40° C. to 20° C. to provide 1-(tert-butyl) 4-ethyl (2S)-2-methyl-3-oxopiperidine-1,4-dicarboxylate.
  • LiHMDS lithium bis(trimethylsilyl)amide
  • a commercially available or synthetically accessible compound of formula (XXV), where R 1 is H, and PG is BOC (tert-butyloxycarbonyl) is reacted with a commercially available or synthetically accessible hydrazine compound of formula R 4 NHNH 2 , where R 4 is C 1-4 alkyl, in AcOH, at a temperature of about 80° C., to provide a pyrazolone compound of formula (XXVIa), where R 4 is C 1-4 alkyl.
  • a commercially available or synthetically accessible compound of formula (XXV), where R 1 is C 1-4 alkyl, and PG is BOC (tert-butyloxycarbonyl) is reacted with a commercially available or synthetically accessible hydrazine compound of formula R 4a NHNH 2 , or salt thereof, where R 4a is C 1-4 alkyl, C 3-6 cycloalkyl or phenyl, in a suitable solvent such as toluene or ethanol with a suitable base such as N,N-diisopropylethylamine (Hünig's base or DIEA), at a temperature of between 80 and 110° C., to provide a pyrazolone compound of formula (XXVIb), where R 4a is C 1-4 alkyl, C 3-6 cycloalkyl or phenyl.
  • a sulfonate-based leaving group such as trifluoromethanesulfonyl (triflate)
  • Tf 2 O trifluoromethanesulfonic anhydride
  • a base such as triethylamine (TEA), pyridine, N-ethyldiisopropylamine (DIEA, DIPEA), and the like; in a suitable solvent such as DCM and the like.
  • Milder triflating agents such as N-phenylbis(trifluoromethanesufonimide) (Tf 2 NPh), a base such as TEA, DIEA, and the like, in a suitable solvent such as DCM, and the like; are used for better selectivity, to provide compounds of formulas (XXVIIa) and (XXVIIb).
  • tert-Butyl 7-methyl-3-oxo-1,2,3,4,5,7-hexahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate is reacted with a triflating agent as previously described to provide tert-butyl 7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate.
  • 3-iodobenzoic acid is reacted with 3-(trifluoromethyl)pyrazole, a base such as cesium carbonate, a copper catalyst such as CuI, a ligand such as trans-N,N′-dimethylcyclohexane-1,2-diamine, in a suitable solvent such as DMF, at temperatures ranging from 100-140° C., under microwave irradiation, to provide 3-[3-(trifluoromethyl)pyrazol-1-yl]benzoic acid.
  • a base such as cesium carbonate
  • a copper catalyst such as CuI
  • a ligand such as trans-N,N′-dimethylcyclohexane-1,2-diamine
  • a compound of formula (XXXI) where R f is halo, C 1-4 alkyl, C 1-4 haloalkyl or OC 1-4 alkyl is reacted with diformylhydrazine, in the presence of trimethylsilyl chloride as a Lewis acid, triethylamine, in a suitable solvent such as pyridine, at a temperature of about 100° C., for a period of about 16 h, to provide the 1,2,4-triazol-4-yl intermediate; in a second step, saponification is achieved according to conditions known to one skilled in the art, or as previously described.
  • 5,8-dihydro-6H-pyrano[3,4-b]pyridine 1-oxide is prepared by oxidizing 5,8-dihydro-6H-pyrano[3,4-b]pyridine (prepared according to procedures described in Tetrahedron, 45(19), 6211-20; 1989) employing conditions known to one skilled in the art.
  • 5,8-dihydro-6H-pyrano[3,4-b]pyridine is reacted with an oxidizing agent such as meta-chloroperoxybenzoic acid (mCPBA), in a suitable solvent such as DCM, at a temperature ranging from 0° C. to 25° C.
  • an oxidizing agent such as meta-chloroperoxybenzoic acid (mCPBA)
  • mCPBA meta-chloroperoxybenzoic acid
  • Halogenation employing a chlorinating agent such as POCl 3 , and the like, in a suitable solvent such as chloroform, and the like, at temperatures ranging from 70-90° C., to affords a mixture of compounds of formula (XXXII) and (XXXIII), where HAL is Cl.
  • Palladium-catalyzed cyanation of (hetero)aryl halide compounds of formula (XXXII) and (XXXIII) is achieved employing zinc cyanide as the nucleophile, zinc, tris(dibenzylideneacetone)dipalladium(0), and 1,1′-bis(diphenylphosphino)ferrocene, in a suitable solvent, at a temperature of about 90° C., for a period of 4 days, to provide 5,8-dihydro-6H-pyrano[3,4-b]pyridine-4-carbonitrile and 5,8-dihydro-6H-pyrano[3,4-b]pyridine-2-carbonitrile.
  • 3,4-Dihydro-2H-pyrano[2,3-b]pyridine-5-carboxylic acid is prepared according to methods previously described starting from 3,4-dihydro-2H-pyrano[2,3-b]pyridine.
  • a compound of formula (XXVIIa), where R 4 is C 1-4 alkyl and PG is BOC; is reacted with a suitably substituted commercially available or synthetically accessible alkyl, cycloalkyl, aryl or heteroaryl boronic acid, boronate ester
  • a compound of formula (XLa), where R 4 is C 1-4 alkyl; and R 2 is quinoline; is prepared by conventional amide bond forming techniques such as coupling reactions which are well known to those skilled in the art (such as HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate), BOP (benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate), or conversion of the acid to an acid chloride).
  • HATU 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
  • BOP benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate
  • Coupling reactions are conducted in a suitable solvent such as DCM, THF, DMF and the like, optionally in the presence of a tertiary amine such as N-methylmorpholine, N-ethyldiisopropylamine (DIEA, DIPEA), or triethylamine (TEA), at a temperature ranging from about 0° C. to rt, to provide compound a of formula (XLa).
  • a compound of (XXXIXb) is reacted in the same fashion as described above to provide compounds of formula (XLb).
  • a compound of formula (XLI), where R 1 is C 1-4 alkyl, and R 3a is phenyl substituted with one, two, or three halo members is prepared by reacting tert-butyl 7-methyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate is in metal-mediated cross coupling reaction employing conditions previously described with a commercially available or synthetically accessible suitably substituted phenyl boronic acid.
  • Diflouromethylation of a compound of formula (XLI) is achieved employing sodium 2-chloro-2,2-difluoroacetate, a suitable base such as NaH, in a solvent such as DMF, and the like, to provide a compound of formula (XLII), where R 4a is CF 2 H.
  • Trifluoromethylation of a compound of formula (XLI) is achieved in two steps.
  • a first step reaction with dibromodifluoromethane, in a suitable solvent such as DMF, in the presence of a suitable base such as NaH, at elevated temperature, provides the 1-bromodifluoromethylated intermediate.
  • a suitable solvent such as DMF
  • silver(I) tetrafluoroborate in a suitable solvent such as DCM, at temperatures ranging from 0° C. to room temperature, provides a compound of formula (XLII), where R 4a is CF 3 .
  • a compound of formula (XXVIIb) is coupled in a metal mediated cross coupling reaction as previously described, with a suitably substituted commercially available or synthetically accessible aryl, alkyl, or heteroaryl boronic acid, to provide a compound of formula (XLIV), where R 3a and R 4a are as described in claim 28 .
  • Subsequent deprotection employing methods previously described provides a compound of formula (XLIII).
  • compounds of Formula (I), or Formula (II), where R 1 , R 2 , R 2a , R 3 , R 3a , R 4 and R 4a are as defined in claim 1 and claim 28 are prepared from compounds of formula (XLV) or (XLIII), according to conventional amide bond forming techniques such as coupling reactions with a suitably substituted aryl or heteroaryl carboxylic acid, which are previously described, or by reaction of suitably substituted aryl or heteroaryl acid chlorides (conversion of the acid to an acid chloride), employing a base such as TEA (triethylamine), and the like, in a suitable solvent such as DCM, THF, ethyl acetate (EtOAc), and the like.
  • a base such as TEA (triethylamine)
  • EtOAc ethyl acetate
  • Subsequent tosylation of the OH moiety employing toluene-p-sulphonic anhydride (Ts 2 O), a base such as TEA (triethylamine), in a suitable solvent provides a tosylated compound which is subsequently fluorinated with [ 18 F]fluoride, as previously described, to provide a compound of Formula (II), where R 2a is an indole substituted with CH 2 CH 2 18 F.
  • a compound of Formula (II), where R 2a is 3-bromopyrazolo[1,5-a]pyridin-4-yl is reacted with trimethylboroxine, a suitable catalyst such as tetrakis(triphenylphosphine)palladium(0), and a suitable base such as potassium carbonate, in a suitable solvent such as N,N-dimethylformamide at 100° C. to provide a compound of Formula (II), where R 2a is 3-methylpyrazolo[1,5-a]pyridin-4-yl.
  • tert-butyl (S)-(1-oxopropan-2-yl)carbamate and methylhydrazine can be condensed in a suitable solvent such as THF to afford tert-butyl (S,E)-(1-(2-methylhydrazineylidene)propan-2-yl)carbamate.
  • a commercially available or synthetically accessible suitably substituted aryl aldehyde of formula (XLVI) is treated with 2-(2-nitroethyl)-1,3-dioxolane in the presence of a catalytic amount of suitable base such as piperidine; in a suitable solvent such as toluene; at a temperature of 110° C. to provide a compound of formula (XLVII), where R 3a and R 4a are as defined in Formula (II).
  • Compounds of Formula (I) may be converted to their corresponding salts using methods known to one of ordinary skill in the art.
  • an amine of Formula (I) (as well as compounds of Formula (II)) is treated with trifluoroacetic acid, HCl, or citric acid in a solvent such as Et 2 O, CH 2 Cl 2 , THF, MeOH, chloroform, or isopropanol to provide the corresponding salt form.
  • trifluoroacetic acid or formic acid salts are obtained as a result of reverse phase HPLC purification conditions.
  • Crystalline forms of pharmaceutically acceptable salts of compounds of Formula (I) may be obtained in crystalline form by recrystallization from polar solvents (including mixtures of polar solvents and aqueous mixtures of polar solvents) or from non-polar solvents (including mixtures of non-polar solvents).
  • the compounds according to this invention may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.
  • Compounds prepared according to the schemes described above may be obtained as single forms, such as single enantiomers, by form-specific synthesis, or by resolution. Compounds prepared according to the schemes above may alternately be obtained as mixtures of various forms, such as racemic (1:1) or non-racemic (not 1:1) mixtures. Where racemic and non-racemic mixtures of enantiomers are obtained, single enantiomers may be isolated using conventional separation methods known to one of ordinary skill in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation. Where regioisomeric or diastereomeric mixtures are obtained, as applicable, single isomers may be separated using conventional methods such as chromatography or crystallization.
  • reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were “dried,” they were generally dried over a drying agent such as Na 2 SO 4 or MgSO 4 . Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM (Microwave Reactor) Discover instrument.
  • “flowed through a LTF-VS mixer” refers to the use of a Chemyx Fusion 100 Touch Syringe Pump that is in line via 1/16′′ PTFE tubing to a LTF-VS mixer (Little Things Factory GmbH (http://www.ltf-gmbh.com), unless otherwise indicated.
  • SFC supercritical fluid high performance liquid chromatography
  • Mass spectra were obtained on an Agilent series 1100 MSD using electrospray ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass corresponds to the exact mass.
  • NMR Nuclear magnetic resonance
  • Step A tert-Butyl 2-methyl-3-oxo-1,4,5,7-tetrahydropyrazolo[3,4-c]pyridine-6-carboxylate
  • Step B tert-Butyl 2-methyl-3-(trifluoromethylsulfonyloxy)-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step C tert-Butyl 2-methyl-3-phenyl-5,7-dihydro-4H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step D 2-Methyl-3-phenyl-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridine
  • Step A 1-(tert-Butyl) 4-ethyl 2-methyl-3-oxopiperidine-1,4-dicarboxylate
  • Step B tert-Butyl 2,7-dimethyl-3-oxo-1,2,3,4,5,7-hexahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step C tert-Butyl-2,7-dimethyl-3-(((trifluoromethyl)sulfonyl)oxy)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step A Ethyl (S)-4-((1-ethoxy-1-oxopropan-2-yl) amino)butanoate
  • reaction mixture was cooled to 20-30° C. and transferred into another reactor followed by adding water (87.5 L, 25 V).
  • the resulting mixture was extracted with tert-butyl methyl ether (MTBE) (17.5 L ⁇ 4).
  • MTBE tert-butyl methyl ether
  • the organic phase was collected and washed with brine (17.5 L).
  • the organic phase was combined with the organic phases from other two batches (1.00 kg batch and 2.50 kg batch). Then the solution was concentrated under vacuum at 40-45° C. to give 6.8 kg of the title compound as a light-yellow oil (94% w/w assay by Q-NMR) in the yield of 82.2%.
  • Step B Ethyl (S)-4-((tert-butoxycarbonyl)(1-ethoxy-1-oxopropan-2-yl)amino)butanoate
  • Step C 1-(tert-Butyl) 4-ethyl (2S)-2-methyl-3-oxopiperidine-1,4-dicarboxylate
  • the resulting reaction mixture was warmed to 10-20° C. and held at this temperature for 1 h. After the completion of the reaction, the reaction mixture was combined with other two batches then poured into aq. citric acid (408.6 g in 2250 mL H 2 O, 2.9 mol, 1.5 eq.). After phase separation, the aqueous layer was re-extracted with MTBE (12 L, 10 V), the combined organic layers were sequentially washed with brine (9 L ⁇ 2). The organic phase was dried over Na 2 SO 4 , then concentrated under vacuum to give crude product.
  • Step D tert-Butyl (7S)-2,7-dimethyl-3-oxo-2,3,3a,4,5,7-hexahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • methylhydrazine sulfate 360 g, 2.5 mol, 1.5 eq.
  • EtOH 5 L, 10.6 V
  • DIEA 399 mL, 2.4 mol, 1.45 eq.
  • the resulting mixture was warmed to 75-80° C. over 30 min.
  • a solution of 1-(tert-butyl) 4-ethyl (2S)-2-methyl-3-oxopiperidine-1,4-dicarboxylate (495 g crude, assay weight 470 g, 1.6 mol, 1.0 eq.) in EtOH (500 mL) was added dropwise over 20 min while keeping the temperature at 75-80° C.
  • Step E (S)-tert-Butyl 2,7-dimethyl-3-(trifluoromethylsulfonyloxy)-4,5-dihydro-2H-pyrazolo[3,4-c]pyridine-6(7H)-carboxylate
  • tert-butyl (7S)-2,7-dimethyl-3-oxo-2,3,3a,4,5,7-hexahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate 940 g, 3.3 mol, 1.0 eq.
  • DCM 6 L, 6.4 V
  • DIEA 550 mL, 3.3 mol, 1.0 eq.
  • N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonimide) 902 g, 2.3 mol, 0.7 eq.
  • N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonimide) 902 g, 2.3 mol, 0.7 eq.
  • Additional N-(5-chloro-2-pyridyl)bis(trifluoromethanesulfonimide) 232 g, 0.6 mol, 0.18 eq.
  • Step A 2-Methyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate
  • Step B 2-Methyl-6-(quinoline-6-carbonyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridin-3-yl trifluoromethanesulfonate
  • a microwave vial was charged with methyl 3-iodoquinoline-6-carboxylate (150 mg, 0.48 mmol), methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (0.15 mL, 1.20 mmol), copper(I) iodide (228 mg, 1.20 mmol), DMPU (0.33 mL, 2.71 mmol), and DMF (3.0 mL).
  • the head space was evacuated under vacuum and refilled with N 2 ( ⁇ 3), and then the reaction mixture was heated under microwave irradiation at 130° C. for 30 min.
  • the reaction mixture was filtered over a pad of diatomaceous earth (Celite®), eluting with MeOH.
  • Step A tert-Butyl 3-(3,5-difluorophenyl)-7-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step B tert-Butyl 3-(3,5-difluorophenyl)-7-methyl-2-(methyl-d3)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step C 3-(3,5-Difluorophenyl)-7-methyl-2-(methyl-d3)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
  • Step A tert-Butyl 2-(difluoromethyl)-3-(3,5-difluorophenyl)-7-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step B 2-(Difluoromethyl)-3-(3,5-difluorophenyl)-7-methyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
  • Step A tert-Butyl (S)-7-methyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step B (S)-2-(Difluoromethyl)-7-methyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
  • Step A tert-Butyl (R)-7-methyl-3-(3,4,5-trifluorophenyl)-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step B (R)-2-(Difluoromethyl)-7-methyl-3-(3,4,5-trifluorophenyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
  • Step A tert-butyl 2-(bromodifluoromethyl)-3-(3,5-difluorophenyl)-7-methyl-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step B 3-(3,5-Difluorophenyl)-7-methyl-2-(trifluoromethyl)-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
  • Step A (E)-2-(3-(3,5-Difluorophenyl)-2-nitroallyl)-1,3-dioxolane
  • Step B tert-Butyl (S,E)-(1-(2-methylhydrazineylidene)propan-2-yl)carbamate
  • Step C tert-Butyl (S)-(1-(4-((1,3-dioxolan-2-yl)methyl)-5-(3,5-difluorophenyl)-1-methyl-1H-pyrazol-3-yl)ethyl)carbamate
  • Step D (S)-3-(3,5-Difluorophenyl)-2,7-dimethyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
  • the extracted organic layer was dried with Na 2 SO 4 , filtered and evaporated to light brown oil.
  • the crude product was diluted in EtOH and 1.1 equivalents of 1 N HCl (10 mL, 10 mmol) was added. The mixture was stirred over weekend without any formation of the HCl salt. The mixture was concentrated to a light brown solid then slurried in minimum 9/1 CH 3 CN/TBME overnight. The solids were filtered to recover the HCl salt of the title compound (1.92 g, 68%).
  • Step A tert-butyl 2-(bicyclo[1.1.1]pentan-1-yl)-7-methyl-3-oxo-1,2,3,4,5,7-hexahydro-6H-pyrazolo[3,4-c]pyridine-6-carboxylate
  • Step B 2-(bicyclo[1.1.1]pentan-1-yl)-7-methyl-3-phenyl-4,5,6,7-tetrahydro-2H-pyrazolo[3,4-c]pyridine
  • Phosphorus(V) oxychloride (6.3 mL, 67.6 mmol) was added to a mixture of 5,8-dihydro-6H-pyrano[3,4-b]pyridine 1-oxide (1.5 g, 9.7 mmol) in chloroform (55 mL). The reaction mixture was refluxed at 80° C. overnight. Then, iced water and aqueous ammonia was added until basic pH was reached. DCM was added to the mixture. The organic layer was separated, dried over MgSO 4 , filtered and concentrated under reduced pressure.
  • Step A (2-(Trimethylsilyl)ethoxy)methyl 5-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-4-carboxylate
  • Step B 5-Trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrrolo[2,3-b]pyridine-4-carboxylic acid
  • Step B 1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid
  • Step B Methyl 3-fluoropyrazolo[1,5-a]pyridine-4-carboxylate
  • Step A Methyl pyrazolo[1,5-a] pyridine-5-carboxylate
  • Step B Methyl 3-fluoropyrazolo[1,5-a] pyridine-5-carboxylate
  • Step C Potassium 3-fluoropyrazolo[1,5-a] pyridine-5-carboxylate
  • Step A Methyl 1-methyl-5-(1-methylcyclopropyl)-1H-pyrazole-4-carboxylate and Methyl 1-methyl-3-(1-methylcyclopropyl)-1H-pyrazole-4-carboxylate
  • Methyl 3-(1-methylcyclopropyl)-3-oxopropanoate 500 mg, 3.20 mmol
  • N,N-dimethylformamide dimethyl acetal (0.51 mL, 3.84 mmol) were stirred together for 1.5 h, then the mixture concentrated in vacuo.
  • EtOH (3.0 mL) and methylhydrazine (0.17 mL, 3.20 mmol) were then added, and the reaction heated to reflux for 1 h before being allowed to stir overnight at room temperature.
  • the mixture was diluted with EtOAc and H 2 O, then the aqueous layer separated and extracted with EtOAc ( ⁇ 2).
  • Step B 1-Methyl-5-(1-methylcyclopropyl)-1H-pyrazole-4-carboxylic acid
  • Step A Ethyl 3-(1-fluorocyclopropyl)-3-oxopropanoate
  • Step B Ethyl 5-(1-fluorocyclopropyl)-1-methyl-1H-pyrazole-4-carboxylate and Ethyl 3-(1-fluorocyclopropyl)-1-methyl-1H-pyrazole-4-carboxylate
  • Step B Potassium 1-methyl-cis-5-(2-methylcyclopropyl)-1H-pyrazole-4-carboxylate
  • Step A Ethyl 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate and Ethyl 1-cyclopropyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate
  • Step B Potassium 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate
  • Step A Ethyl 2-cyclopropyl-7-methylpyrazolo[1,5-a] pyridine-3-carboxylate
  • Step B Potassium 2-cyclopropyl-7-methylpyrazolo[1,5-a] pyridine-3-carboxylate
  • Step A ethyl 7-fluoro-2-methylimidazo[1,2-a] pyridine-3-carboxylate
  • Step B Potassium 7-fluoro-2-methylimidazo[1,2-a] pyridine-3-carboxylate
  • Step A 1-Amino-2-methylpyrazin-1-ium 2,4,6-trimethylbenzenesulfonate
  • Step B Ethyl 2,4-dimethylpyrazolo[1,5-a] pyrazine-3-carboxylate
  • Step C Potassium 2,4-dimethylpyrazolo[1,5-a] pyrazine-3-carboxylate
  • Step A methyl 5,7-dimethyl-7H-pyrrolo[2,3-d] pyrimidine-4-carboxylate
  • Step B Potassium 5,7-dimethyl-7H-pyrrolo[2,3-d] pyrimidine-4-carboxylate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
US16/586,088 2018-09-28 2019-09-27 Monoacylglycerol Lipase Modulators Abandoned US20200102303A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US16/586,088 US20200102303A1 (en) 2018-09-28 2019-09-27 Monoacylglycerol Lipase Modulators
US17/132,313 US11820766B2 (en) 2018-09-28 2020-12-23 Monoacylglycerol lipase modulators
US18/062,484 US20230145249A1 (en) 2018-09-28 2022-12-06 Monoacylglycerol Lipase Modulators

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862738600P 2018-09-28 2018-09-28
US16/586,088 US20200102303A1 (en) 2018-09-28 2019-09-27 Monoacylglycerol Lipase Modulators

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/132,313 Continuation US11820766B2 (en) 2018-09-28 2020-12-23 Monoacylglycerol lipase modulators

Publications (1)

Publication Number Publication Date
US20200102303A1 true US20200102303A1 (en) 2020-04-02

Family

ID=68109428

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/586,088 Abandoned US20200102303A1 (en) 2018-09-28 2019-09-27 Monoacylglycerol Lipase Modulators
US17/132,313 Active US11820766B2 (en) 2018-09-28 2020-12-23 Monoacylglycerol lipase modulators
US18/062,484 Pending US20230145249A1 (en) 2018-09-28 2022-12-06 Monoacylglycerol Lipase Modulators

Family Applications After (2)

Application Number Title Priority Date Filing Date
US17/132,313 Active US11820766B2 (en) 2018-09-28 2020-12-23 Monoacylglycerol lipase modulators
US18/062,484 Pending US20230145249A1 (en) 2018-09-28 2022-12-06 Monoacylglycerol Lipase Modulators

Country Status (23)

Country Link
US (3) US20200102303A1 (es)
EP (1) EP3856178A1 (es)
JP (1) JP7482116B2 (es)
KR (1) KR20210069080A (es)
CN (1) CN113164459A (es)
AU (1) AU2019350624A1 (es)
BR (1) BR112021005896A2 (es)
CA (1) CA3111380A1 (es)
CL (1) CL2021000757A1 (es)
CO (1) CO2021003944A2 (es)
CR (1) CR20210153A (es)
EA (1) EA202190886A1 (es)
EC (1) ECSP21021381A (es)
IL (1) IL281812A (es)
JO (1) JOP20210058A1 (es)
MA (1) MA53721A (es)
MX (1) MX2021003737A (es)
NI (1) NI202100023A (es)
PE (1) PE20211773A1 (es)
PH (1) PH12021550659A1 (es)
SG (1) SG11202102281VA (es)
TW (1) TW202028198A (es)
WO (1) WO2020065613A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
WO2020065614A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
KR20210069080A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
CN114555596A (zh) * 2019-09-30 2022-05-27 詹森药业有限公司 放射性标记的mgl pet配体
JP2023518511A (ja) 2020-03-26 2023-05-01 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子
WO2022150962A1 (en) * 2021-01-12 2022-07-21 Westlake Pharmaceutical (Hangzhou) Co., Ltd. Protease inhibitors, preparation, and uses thereof
AR127955A1 (es) 2021-12-16 2024-03-13 Hoffmann La Roche Nuevos compuestos heterocíclicos
CN115872995A (zh) * 2022-12-27 2023-03-31 上海凌凯医药科技有限公司 一种吡唑并吡啶化合物及一种羧酸衍生物的制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812462A (en) 1986-04-01 1989-03-14 Warner-Lambert Company 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity
US4816463A (en) 1986-04-01 1989-03-28 Warner-Lambert Company Substituted diimidazo [1,5-a: 4',5'-d]pyridines having antihypertensive activity
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
US8933236B2 (en) 2012-05-22 2015-01-13 Xenon Pharmaceuticals Inc. N-substituted benzamides and methods of use thereof
JP2005537290A (ja) 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
MXPA05000947A (es) 2002-07-25 2005-05-16 Pharmacia Italia Spa Biciclo-pirazoles activos como inhibidores de cinasa, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
AR045037A1 (es) 2003-07-10 2005-10-12 Aventis Pharma Sa Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
FR2857363B1 (fr) 2003-07-10 2007-09-07 Aventis Pharma Sa 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
US7625888B2 (en) 2004-08-23 2009-12-01 Merck & Co., Inc. Fused triazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
WO2006080884A1 (en) 2005-01-27 2006-08-03 Astrazeneca Ab Novel biaromatic compounds, inhibitors of the p2x7-receptor
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
WO2006110516A1 (en) 2005-04-11 2006-10-19 Abbott Laboratories Acylhydrazide p2x7 antagonists and uses thereof
US7943617B2 (en) 2006-11-27 2011-05-17 Bristol-Myers Squibb Company Heterobicyclic compounds useful as kinase inhibitors
PE20090418A1 (es) 2007-06-21 2009-04-18 Schering Corp Derivados de guanina policiclicos y sus metodos de uso
EP2185560A4 (en) 2007-08-10 2011-10-05 Lundbeck & Co As H HETEROARYLAMIDANALOGE
FR2921342B1 (fr) 2007-09-20 2010-03-12 Airbus France Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
EP2090576A1 (en) 2008-02-01 2009-08-19 Merz Pharma GmbH & Co.KGaA 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
US8431704B2 (en) 2008-04-22 2013-04-30 Janssen Pharmaceutica Nv Quinoline or isoquinoline substituted P2X7 antagonists
EP2370437B1 (en) 2008-11-25 2013-09-04 Nerviano Medical Sciences S.r.l. Bicyclic pyrazole and isoxazole derivatives as antitumor and antineurodegenerative agents
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
TW201103914A (en) * 2009-04-22 2011-02-01 Janssen Pharmaceutica Nv Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors
JP5654001B2 (ja) 2009-04-29 2015-01-14 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐ２Ｘ７調節因子としての５，６，７，８−テトラヒドロ［１，２，４］トリアゾロ［４，３−ａ］ピラジン誘導体
GB0907515D0 (en) 2009-04-30 2009-06-10 Glaxo Group Ltd Compounds
US8871760B2 (en) 2009-09-21 2014-10-28 Roche Palo Alto Llc [1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
JP5848251B2 (ja) 2009-10-23 2016-01-27 ヤンセン ファーマシューティカ エヌ．ベー． オレキシン受容体調節因子としての縮合複素環式化合物
WO2011103715A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Task channel antagonists
ES2627688T3 (es) 2010-04-02 2017-07-31 Ogeda Sa Novedosos compuestos antagonistas selectivos del receptor de NK-3, composición farmacéutica y métodos para uso en trastornos mediados por los receptores de NK-3
CA2796211A1 (en) 2010-04-16 2011-10-20 Rodrigo Graf Fernandez Foldable structures for a construction
EP2619204A4 (en) 2010-09-21 2014-08-27 Merck Sharp & Dohme TRIAZOLOPYRAZINONES AS ANTAGONISTS OF P2X7 RECEPTORS
US8575363B2 (en) 2010-10-22 2013-11-05 Janssen Pharmaceutica N.V. Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US9273947B2 (en) 2012-02-07 2016-03-01 Lg Innotek Co., Ltd. Sensing magnet apparatus for motor
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
JO3459B1 (ar) 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN110041250A (zh) 2012-10-15 2019-07-23 Epizyme股份有限公司 经取代的苯化合物
MX358508B (es) 2012-10-16 2018-08-22 Janssen Pharmaceutica Nv Moduladores de quinolinilo unidos a metileno de receptor nuclear de acido retinoico-gamma-t.
CN107936039A (zh) 2012-11-01 2018-04-20 因赛特公司 作为jak抑制剂的三环稠合噻吩衍生物
US9796729B2 (en) 2012-11-23 2017-10-24 Glaxosmithkline Llc Compounds as diacylglycerol acyltransferase inhibitors
SG11201504946VA (en) 2012-12-21 2015-07-30 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
HUE036739T2 (hu) 2012-12-21 2018-07-30 Plexxikon Inc Vegyületek és eljárások kináz modulációra, és azok indikációi
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
AU2014225675B2 (en) 2013-03-06 2018-10-04 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine modulators of the histamine H4 receptor
NO335177B1 (no) 2013-03-06 2014-10-13 Cambi Technology As Fremgangsmåte og anordning for termisk biologisk nedbryting og avvanning av biomasse
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
SG11201507395PA (en) 2013-03-14 2015-10-29 Curadev Pharma Private Ltd Inhibitors of the kynurenine pathway
PE20151593A1 (es) 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
US9096596B2 (en) 2013-03-14 2015-08-04 Janssen Pharmaceutica Nv P2X7 modulators
HUE053431T2 (hu) 2013-03-14 2021-07-28 Boehringer Ingelheim Int Szubsztituált 2-aza-biciklo[2.2.1]heptán-3-karbonsav-(benzil-ciano-metil)-amidok, mint a katepszin-C inhibitorai
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
JO3383B1 (ar) 2013-03-14 2019-03-13 Lilly Co Eli مثبطات cdc7
KR101780784B1 (ko) 2013-03-14 2017-09-21 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 2,3-이치환된 1-아실-4-아미노-1,2,3,4-테트라하이드로퀴놀린 유도체 및 이의 브로모도메인 억제제로서의 용도
US9840508B2 (en) 2013-03-29 2017-12-12 Oged Sa N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
EP3036229A1 (en) 2013-08-22 2016-06-29 F. Hoffmann-La Roche AG Alkynyl alcohols and methods of use
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
EA034015B1 (ru) 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
CA2960972C (en) 2014-09-12 2023-10-03 Janssen Pharmaceutica Nv P2x7 modulating n-acyl-triazolopyrazines
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
KR20210069080A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
WO2020065614A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
WO2020211798A1 (zh) 2019-04-16 2020-10-22 上海翰森生物医药科技有限公司 含二并环类衍生物抑制剂、其制备方法和应用
CN114555596A (zh) 2019-09-30 2022-05-27 詹森药业有限公司 放射性标记的mgl pet配体
JP2023518511A (ja) 2020-03-26 2023-05-01 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子

Also Published As

Publication number Publication date
US11820766B2 (en) 2023-11-21
EA202190886A1 (ru) 2021-09-07
AU2019350624A1 (en) 2021-03-18
CL2021000757A1 (es) 2021-08-27
CN113164459A (zh) 2021-07-23
TW202028198A (zh) 2020-08-01
WO2020065613A1 (en) 2020-04-02
MA53721A (fr) 2021-09-15
BR112021005896A2 (pt) 2021-07-27
ECSP21021381A (es) 2021-04-29
CO2021003944A2 (es) 2021-04-19
SG11202102281VA (en) 2021-04-29
NI202100023A (es) 2021-09-07
EP3856178A1 (en) 2021-08-04
US20220332713A1 (en) 2022-10-20
US20230145249A1 (en) 2023-05-11
CR20210153A (es) 2021-05-11
CA3111380A1 (en) 2020-04-02
JP7482116B2 (ja) 2024-05-13
IL281812A (en) 2021-05-31
MX2021003737A (es) 2021-05-14
KR20210069080A (ko) 2021-06-10
PE20211773A1 (es) 2021-09-08
JP2022502424A (ja) 2022-01-11
PH12021550659A1 (en) 2022-02-21
JOP20210058A1 (ar) 2021-03-24

Similar Documents

Publication Publication Date Title
US11820766B2 (en) Monoacylglycerol lipase modulators
KR102500076B1 (ko) P2x7 조절제
US11993601B2 (en) Monoacylglycerol lipase modulators
KR20190056435A (ko) 치환된 1H-이미다조[4,5-b]피리딘-2(3H)-온 및 GLUN2B 수용체 조절제로서의 이의 용도
CA2790847A1 (en) Fused bicyclic kinase inhibitors
US11891387B2 (en) Monoacylglycerol lipase modulators
CA3198809A1 (en) Heterocyclic spiro compounds and methods of use
TW202115075A (zh) 咪唑并[1,2-a]吡啶基衍生物及其在疾病治療中之用途
US20220306640A1 (en) Hydantoin derivative
US20230339970A1 (en) Casein kinase 1 delta modulators
RU2797323C2 (ru) Модуляторы моноацилглицеринлипазы
US20240228484A1 (en) Monoacylglycerol lipase modulators

Legal Events

Date Code Title Description
AS Assignment

Owner name: JANSSEN PHARMACEUTICA NV, BELGIUM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:AMERIKS, MICHAEL K.;CHEN, GANG;HUANG, CHAOFENG;AND OTHERS;SIGNING DATES FROM 20190918 TO 20190926;REEL/FRAME:050608/0682

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION